Pasithea Therapeutics Announces 5 Million Private Placement Priced At-The-Market Under Nasdaq Rules
KTTA Stock | USD 2.54 0.12 4.51% |
About 55% of Pasithea Therapeutics' investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Pasithea Therapeutics Corp suggests that some traders are interested. The current market sentiment, together with Pasithea Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Pasithea Therapeutics stock news signals to limit their universe of possible portfolio assets.
Pasithea |
MIAMI, Sept. 26, 2024 -- Pasithea Therapeutics Corp. , a clinical-stage biotechnology...
Read at globenewswire.com
Pasithea Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Pasithea Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Pasithea Therapeutics Fundamental Analysis
We analyze Pasithea Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pasithea Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pasithea Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Gross Profit
Gross Profit Comparative Analysis
Pasithea Therapeutics is currently under evaluation in gross profit category among its peers. Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Pasithea Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Pasithea Therapeutics stock to make a market-neutral strategy. Peer analysis of Pasithea Therapeutics could also be used in its relative valuation, which is a method of valuing Pasithea Therapeutics by comparing valuation metrics with similar companies.
Peers
Pasithea Therapeutics Related Equities
ABVC | ABVC Biopharma | 8.33 | ||||
QNRX | Quoin Pharmaceuticals | 7.14 | ||||
NTRBW | Nutriband Warrant | 6.12 | ||||
RNXT | RenovoRx | 3.60 | ||||
MNOV | MediciNova | 0.94 | ||||
KRON | Kronos Bio | 0.32 | ||||
INDP | Indaptus Therapeutics | 0.22 | ||||
REVB | Revelation Biosciences | 2.65 | ||||
KZR | Kezar Life | 3.53 | ||||
KPRX | Kiora Pharmaceuticals | 6.59 | ||||
FBRX | Forte Biosciences | 10.07 | ||||
VRAX | Virax Biolabs | 18.99 |
Complementary Tools for Pasithea Stock analysis
When running Pasithea Therapeutics' price analysis, check to measure Pasithea Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pasithea Therapeutics is operating at the current time. Most of Pasithea Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pasithea Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pasithea Therapeutics' price. Additionally, you may evaluate how the addition of Pasithea Therapeutics to your portfolios can decrease your overall portfolio volatility.
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Content Syndication Quickly integrate customizable finance content to your own investment portal | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |